In summary, Dectin-1 can amplify anti-tumor immunity through coordinated reprogramming of multiple immune compartments such as macrophages, DCs, NK cells, Th9 cells, and B cells, largely via SYK–CARD9–NF-κB–dependent pathways and ligand-driven activation by β-glucans. The gene discussed is CARD9; the disease is neoplasm.